Arch Coal Inc (ACI), Vital Therapies Inc (VTL) Making Big Gains Today For Very Different Reasons

Moving on to Vital Therapies Inc (NASDAQ:VTL), the company announced that two investigators presented additional data from its clinical trial of VTI-208 at the 16th International Symposium on Albumin Dialysis in Liver Disease, held on August 29 in Rostock, Germany. The biopharmaceutical company further added that it will continue the analysis of the VTI-208 data set and will design a new clinical phase-3 trial for the experimental drug. Vital Therapies Inc (NASDAQ:VTL) announced the failure of a phase-3 clinical trial of VTI-208 on August 21, indicating no difference in the treated and control subjects participating in the study.

The smart money was also bullish on the stock of the medical company during the second quarter, with their holdings rising by 50.80% to $2.85 million during the quarter. The hedge fund ownership also rose by three in the quarter, as four hedge funds reported positions in the company. What makes these gains even more important is the decline of 15.63% in its share price during the second quarter. D E Shaw was the largest shareholder of Vital Therapies Inc (NASDAQ:VTL) in our database, with ownership of 81,551 shares. Renaissance Technologies, led by Jim Simons, had 17,889 shares of the company in its own portfolio.

Disclosure: None